Good Clinical Approach: Delphi Consensus for the Use of Betahistine in Menière’s Disease

Table 3

Results of the Consensus Conference on the role of betahistine in the therapy of long lasting hearing loss, fullness and tinnitus. 1 = absolutely disagree, 2 = disagree, 3 = agree, 4 = more than agree, and 5 = absolutely agree. Consensus was reached when the sum of items 1 and 2 or 3, 4, and 5 reached 66%. Same asterisk convention.

	1	2	3	4	5
In the therapy of hearing loss in the Menière’s disease, do you think that betahistine:
1. Is the first-choice drug in monotherapy	31%	29%	33%	0%	7%
	60		40
2. Is useful when associated to other therapies in the early stages and in the advanced phases of the disease	18%	22%	50%	4%	6%
	40		60
3. Is useful when associated to other therapies ONLY in the early stages of the disease	11%	26%	44%	14%	5%
	37		63
4. Shows poor efficacy	2%	17%	52%	12%	17%
	19		81
In the therapy of tinnitus in the Menière’s disease, do you think that betahistine:
1. Is the first-choice drug in monotherapy	13%	50%	26%	7%	4%
	63		37
2. Is useful when associated to other therapies	6%	23%	51%	13%	7%
	29		71
3. Is not useful	10%	53%	27%	7%	3%
	63		37
4. Shows poor efficacy	7%	34%	46%	7%	6%
	41		59